Vertex Pharmaceuticals has reported groundbreaking results from its Phase I/II study of zimislecel (VX-880), an iPSC-derived islet cell therapy showing transformative potential for type 1 diabetes (T1D) patients. In the 14-patient trial involving adults with impaired hypoglycemia awareness and recurrent severe hypoglycemic events, the treatment yielded unprecedented outcomes. At one-year follow-up, all participants maintained HbA1c levels below 7%, with 93.3% achieving optimal time-in-range metrics. Most remarkably, 83% of patients (10 of 12) achieved complete insulin independence by month 12, while all subjects reduced their exogenous insulin use by an average of 92%.

The therapy demonstrated durable biological activity, with sustained increases in fasting and stimulated C-peptide levels indicating restored endogenous insulin production. Safety data showed good tolerability, with most adverse events being mild/moderate and related to the required immunosuppressive regimen rather than the cell therapy itself.

With the Phase III portion of the FORWARD-101 study already completed, Vertex anticipates submitting regulatory applications next year. These results represent a potential paradigm shift in type 1 diabetes management, moving beyond insulin replacement to actual disease modification through functional islet cell restoration.